Novartis' Pharmaceutical Business Faces 2 Major Challenges

24-10-2013 DailyFinanceComments (0)


Looking forward, Novartis' pharmaceutical segment has positive growth catalysts, such as positive phase 3 data for its new psoriasis drug secukinumab and a breakthrough designation for its pipeline candidate BYM338 as a treatment for sporadic inclusion ...

Read more on DailyFinance

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top